Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer

Over the last few decades there was a little progress in the treatment of small cell lung cancer (SCLC). But now the approaches are changing with immune checkpoint inhibitors coming into clinical practice. Using a combination of immunotherapy with the standard chemotherapy in the first line of exten...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Galina B. Statsenko, Vyacheslav I. Kurakin, Irina V. Plokhotenko
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2020
Materias:	small cell lung cancer immune checkpoint inhibitor immunotherapy durvalumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8d48bbd873984fc38fbcc51025018cde
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8d48bbd873984fc38fbcc51025018cde
record_format	dspace
spelling	oai:doaj.org-article:8d48bbd873984fc38fbcc51025018cde2021-11-30T17:03:34ZClinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer1815-14341815-144210.26442/18151434.2020.2.200222https://doaj.org/article/8d48bbd873984fc38fbcc51025018cde2020-07-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/34963/23380https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Over the last few decades there was a little progress in the treatment of small cell lung cancer (SCLC). But now the approaches are changing with immune checkpoint inhibitors coming into clinical practice. Using a combination of immunotherapy with the standard chemotherapy in the first line of extensive stage small cell lung cancer (ES-SCLC) results in significant overall survival improvement, for the first time the median survival in these patients exceeded one year. Here we present a clinical case of ES-SCLC patient treated with durvalumab, a monoclonal antibody against PD-L1, in combination with etoposide and carboplatin in the CASPIAN clinical trial. In the CASPIAN trial more than 20% of patients treated with durvalumab stay alive more than two years. In the presented case we also reported durable control of the disease, the patient continued to receive durvalumab of more than two years with acceptable tolerability.Galina B. StatsenkoVyacheslav I. KurakinIrina V. PlokhotenkoIP Habib O.N.articlesmall cell lung cancerimmune checkpoint inhibitorimmunotherapydurvalumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 2, Pp 112-115 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	small cell lung cancer immune checkpoint inhibitor immunotherapy durvalumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	small cell lung cancer immune checkpoint inhibitor immunotherapy durvalumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Galina B. Statsenko Vyacheslav I. Kurakin Irina V. Plokhotenko Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
description	Over the last few decades there was a little progress in the treatment of small cell lung cancer (SCLC). But now the approaches are changing with immune checkpoint inhibitors coming into clinical practice. Using a combination of immunotherapy with the standard chemotherapy in the first line of extensive stage small cell lung cancer (ES-SCLC) results in significant overall survival improvement, for the first time the median survival in these patients exceeded one year. Here we present a clinical case of ES-SCLC patient treated with durvalumab, a monoclonal antibody against PD-L1, in combination with etoposide and carboplatin in the CASPIAN clinical trial. In the CASPIAN trial more than 20% of patients treated with durvalumab stay alive more than two years. In the presented case we also reported durable control of the disease, the patient continued to receive durvalumab of more than two years with acceptable tolerability.
format	article
author	Galina B. Statsenko Vyacheslav I. Kurakin Irina V. Plokhotenko
author_facet	Galina B. Statsenko Vyacheslav I. Kurakin Irina V. Plokhotenko
author_sort	Galina B. Statsenko
title	Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
title_short	Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
title_full	Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
title_fullStr	Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
title_full_unstemmed	Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
title_sort	clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
publisher	IP Habib O.N.
publishDate	2020
url	https://doaj.org/article/8d48bbd873984fc38fbcc51025018cde
work_keys_str_mv	AT galinabstatsenko clinicalcaseoflongtermuseofdurvalumabinthetreatmentofadvancedsmallcelllungcancer AT vyacheslavikurakin clinicalcaseoflongtermuseofdurvalumabinthetreatmentofadvancedsmallcelllungcancer AT irinavplokhotenko clinicalcaseoflongtermuseofdurvalumabinthetreatmentofadvancedsmallcelllungcancer
_version_	1718406392925126656

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer

Ejemplares similares